Author

L. Piccoli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Microbiology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Organism:human· 6 Assay:proteomics· 6 Research Focus:host-pathogen & immune response· 5 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:statistical model· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

E. Cameroni· 5 shared J. Bassi· 5 shared K. Culap· 5 shared A. Ceschi· 4 shared C. Garzoni· 4 shared C. Silacci-Fregni· 4 shared D. Pinto· 4 shared N. Czudnochowski· 4 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

E. Cameroni

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

bioRxiv · Jan 17, 2023 · PreprintImmunology

Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape

R. Marzi, J. Bassi, C. Silacci-Fregni, I. Bartha, F. Muoio, K. Culap, N. Sprugasci, G. Lombardo, C. Saliba, E. Cameroni, A. Cassotta, J. S. Low, A. C. Walls, M. McCallum, M. A. Tortorici, , L. Piccoli

The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.

bioRxiv · Sep 30, 2022Immunology

Extremely potent human monoclonal antibodies for the prophylaxis and therapy of Tetanus

M. Pirazzini, A. Grinzato, D. Corti, S. Barbieri, O. Leka, F. Vallese, M. Tonellato, C. Silacci Fregni, L. Piccoli, E. Kandiah, G. Schiavo, G. Zanotti, A. Lanzavecchia, C. Montecucco

This study identifies two human monoclonal antibodies with high neutralizing activity against tetanus neurotoxin, showing potential for both prophylaxis and therapy.

bioRxiv · May 24, 2021Pathology

A rationally designed oral vaccine induces Immunoglobulin A in the murine gut that directs the evolution of attenuated Salmonella variants

M. Diard, E. Bakkeren, D. Hoces, V. Lentsch, M. Arnoldini, F. Boehi, K. Schumann-Moor, J. Adamcik, L. Piccoli, A. Lanzavecchia, B. Stadtmueller, N. Donohue, M. Vanderwoude, P. Viollier, L. Falquet, , E. Slack

This paper shows that an oral vaccine inducing IgA in mice can direct Salmonella to evolve into less virulent variants with shorter O-antigens.

bioRxiv · May 13, 2021Immunology

A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery

D. Pinto, M. M. Sauer, N. Czudnochowski, J. S. Low, M. A. Tortorici, M. P. Housley, J. Noack, A. C. Walls, J. E. Bowen, B. Guarino, L. E. Rosen, J. di Iulio, J. Jerak, H. Kaiser, S. Islam, , Lanzave

This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.

bioRxiv · May 9, 2021 · PreprintImmunology

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429

M. McCallum, J. Bassi, A. De Marco, A. Chen, A. C. Walls, J. Di Iulio, M. A. Tortorici, M.-J. Navarro, C. Silacci-Fregni, C. Saliba, M. Agostini, D. Pinto, K. Culap, S. Bianchi, S. Jaconi, , D. Veesler

This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.

bioRxiv · Mar 31, 2021 · PreprintImmunology

The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity

E. C. Thomson, L. E. Rosen, J. G. Shepherd, R. Spreafico, A. da Silva Filipe, J. A. Wojcechowskyj, C. Davis, L. Piccoli, D. J. Pascall, J. Dillen, S. Lytras, N. Czudnochowski, R. Shah, M. Meury, N. Jesudason, , J. Nichols

The paper shows the N439K SARS-CoV-2 spike variant maintains replication fitness while evading antibody neutralization.

bioRxiv · Nov 4, 2020Microbiology